Mark Dybul

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10 Rm 11B 13, Bethesda, MD 20892, USA
    J Infect Dis 185:1818-21. 2002
  2. ncbi request reprint Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily
    Susan Moir
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 200:587-99. 2004
  3. ncbi request reprint A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA
    J Infect Dis 189:1974-82. 2004
  4. ncbi request reprint Guidelines for using antiretroviral agents among HIV-infected adults and adolescents
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    Ann Intern Med 137:381-433. 2002
  5. pmc Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:3229-37. 2003
  6. doi request reprint Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy
    Elizabeth Nies-Kraske
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, USA
    J Infect Dis 199:1648-56. 2009
  7. ncbi request reprint Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 188:388-96. 2003
  8. pmc Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda
    Steven J Reynolds
    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Antivir Ther 14:293-7. 2009
  9. pmc Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2
    Christiana Iyasere
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1876, USA
    J Virol 77:10900-9. 2003
  10. pmc Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily
    Susan Moir
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 6A02, 10 Center Dr, Bethesda, MD 20892, USA
    J Exp Med 200:587-99. 2004

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10 Rm 11B 13, Bethesda, MD 20892, USA
    J Infect Dis 185:1818-21. 2002
    ..This in turn could impact efforts to reduce transmission, and it could impact the prognosis for patients who receive antiretroviral therapy...
  2. ncbi request reprint Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily
    Susan Moir
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 200:587-99. 2004
    ....
  3. ncbi request reprint A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA
    J Infect Dis 189:1974-82. 2004
    ..Adherence to such a regimen may be problematic for certain patients...
  4. ncbi request reprint Guidelines for using antiretroviral agents among HIV-infected adults and adolescents
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    Ann Intern Med 137:381-433. 2002
    ..Because concepts regarding HIV management are evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information Service website ( http://www.hivatis.org )...
  5. pmc Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:3229-37. 2003
    ..In addition, the data suggest that there may be multiple compartments contributing to the rebound of plasma viremia and to viral diversity from cycle to cycle of intermittent therapy...
  6. doi request reprint Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy
    Elizabeth Nies-Kraske
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, USA
    J Infect Dis 199:1648-56. 2009
    ..All 4 patients had significant fibrosis of the T cell zone of lymphoid tissue, which appeared to be an important factor in the failure to reconstitute T cells...
  7. ncbi request reprint Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 188:388-96. 2003
    ..There was no clear autoimmunization effect by immunologic or virologic parameters. There was no benefit to long-cycle SIT versus continuous HAART with regard to certain toxicity, immunologic, or virologic parameters...
  8. pmc Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda
    Steven J Reynolds
    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Antivir Ther 14:293-7. 2009
    ..This study aimed to determine the extent of viral resistance over time among non-clade B HIV type-1-infected patients in Uganda who were maintained on first-line highly active antiretroviral therapy (HAART) following virological failure...
  9. pmc Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2
    Christiana Iyasere
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1876, USA
    J Virol 77:10900-9. 2003
    ..These results also suggest that relatively high frequencies of HIV-specific CD4(+) T cells persist in the peripheral blood during viremia, are not replicatively senescent, and proliferate when IL-2 is provided exogenously...
  10. pmc Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily
    Susan Moir
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 6A02, 10 Center Dr, Bethesda, MD 20892, USA
    J Exp Med 200:587-99. 2004
    ....
  11. pmc Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma
    Angela Malaspina
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:8855-63. 2002
    ..These findings also indicate that most of the virus in plasma originates from cells other than CD4(+) T cells in the peripheral blood and lymph nodes...
  12. ncbi request reprint Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    MMWR Recomm Rep 51:1-55. 2002
    ..Because concepts regarding HIV management are evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information Service website (http://www.hivatis.org)...
  13. ncbi request reprint HIV preferentially infects HIV-specific CD4+ T cells
    Daniel C Douek
    Vaccine Research Center, NIAID, NIH, Maryland 20892, USA
    Nature 417:95-8. 2002
    ..Furthermore, the phenomenon of HIV specifically infecting the very cells that respond to it adds a cautionary note to the practice of structured therapy interruption...
  14. ncbi request reprint Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 185:61-8. 2002
    ..Thus, although intermittent IL-2 plus HAART quantitatively increased CD4+ T cells, this increase was not selective for HIV-specific CD4+ or CD8+ T cell responses in recently infected persons...
  15. ncbi request reprint Selected topics from the 10th Conference on Retroviruses and Opportunistic Infections
    Mark Dybul
    HIV Clin Trials 4:282-6. 2003
  16. ncbi request reprint Developing an evidence-based, preventive care package for persons with HIV in Africa
    Jonathan Mermin
    CDC Uganda, Global AIDS Program, National Center for HIV, STD and TB Prevention Centers for Disease Control and Prevention, Entebbe, Uganda
    Trop Med Int Health 10:961-70. 2005
    ..The provision of a basic care package could be an important step toward reducing health care disparities and gaining more control of the global HIV/AIDS epidemic...
  17. ncbi request reprint Rapid expansion of the health workforce in response to the HIV epidemic
    Badara Samb
    World Health Organization, Geneva
    N Engl J Med 357:2510-4. 2007